Drugs / LY3549492
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07232732 | Oct 2025 → Jul 2026 overdue | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07073170 | Jul 2025 → Jan 2026 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06869018 | May 2025 → Mar 2026 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06194500 | Jan → Feb 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05327595 | May 2022 → Apr 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04758234 | Feb 2021 → Jan 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07085468 | Jul → Aug 2025 | — | Eli Lilly and Company | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT07030868 | Jun → Jul 2025 | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT06683508 | Nov 2024 → Jan 2026 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT06143956 | Nov 2023 → Sep 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3549492 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05327595 ↗ |
| Route | Oral | “Administered orally.” NCT04758234 ↗ |